7MM Ovarian Cancer Therapeutics Marketplace Analysed by GlobalData in Its In-Demand Research Report Available at MarketPublishers.com
02 Aug 2017 • by Natalie Aster
LONDON – Over a number of years, the ovarian cancer drug market has been quite stagnant, primarily owing to the increase usage of generic medications and a dearth of successful development of new innovative treatment options. Nevertheless, the market is seeing diversification, supported by recent approvals of Avastin and the poly ADP-ribose polymerase (PARP) inhibitors Rubraca (rucaparib), Lynparza (olaparib), and Zejula (niraparib). New insight on the biology and heterogeneity of ovarian cancer has resulted in the progressive development of novel targeted therapies, IO drugs, and next-gen chemical therapies. A more profound understanding of the tumour microenvironment is poised to take place in the years to come, which is set to further stimulate the successful evolution of novel patient-specific therapies. A total of 9 novel entrants are expected to be launched through to 2025. Competition is likely to be specifically fierce among PARP inhibitors as they keep on establishing their position in the paradigm of the treatment of ovarian cancer.
In-demand report “OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025” created by GlobalData’s gives an overview of ovarian cancer, covering epidemiology, pathophysiology, etiology, symptoms, diagnosis, and today’s management strategies.
The study provides top-line ovarian cancer market revenue figures from 2015-2025; includes data on the annual cost of therapy and the sales of key pipeline products over the projected period. The report sheds light on the key topics such as current treatment modalities, unmet needs and opportunities, and the driving and restraining factors affecting the sales of ovarian cancer therapeutics in the 7MM. It includes a detailed pipeline analysis, with comprehensive data broken down across different phases, emerging new trends, reviews of innovative projects in early-stage pipeline, and a granular analysis of products in late-stage development. The research discusses the existing and future competition across the 7MM ovarian cancer therapeutics market. It comprehensively reviews key industry drivers, limiters, and challenges; with each trend independently analysed to give a qualitative assessment of its implications.
More in-demand reports by this publisher can be found at GlobalData page at MarketPublishers.com.